Abstract
For ages aspirin has established its value as an analgesic, anti-inflammatory drug, but in 1938, it was found to be a causative factor of gastric inflammation (ulcer). Later discovered non-steroidal anti-inflammatory drugs (NSAIDs) were found effective as aspirin but failed to overcome the goal of safer aspirin. As the method of prostaglandin inhibition through COX is a common mechanism to both the wanted and unwanted effects of aspirin and non-aspirin NSAIDs, the COX enzyme becomes a target for drug designers for the development of the “safe aspirin”. In the late 1990s, a new class of drug molecules collectively known as selective inhibitors of cyclooxygenase-2(Coxibs) was developed for the treatment of pain and inflammation. Coxibs developed were as efficacious as the common NSAIDs, but they are devoid of major side effect, the gastrointestinal bleeding. This review presents an overview on all the discovered COX-2 inhibitors, their physiological role, side effects and reasons of their withdrawal.
Keywords: Coxib, cyclooxygenase, gastric bleeding, prostaglandin.
Current Drug Discovery Technologies
Title:Selective Cyclooxygenase Inhibitors: Current Status
Volume: 11 Issue: 2
Author(s): Ravindran Nandakishore, Prasanna R. Yalavarthi, Yengala R. Kiran and Malepati Rajapranathi
Affiliation:
Keywords: Coxib, cyclooxygenase, gastric bleeding, prostaglandin.
Abstract: For ages aspirin has established its value as an analgesic, anti-inflammatory drug, but in 1938, it was found to be a causative factor of gastric inflammation (ulcer). Later discovered non-steroidal anti-inflammatory drugs (NSAIDs) were found effective as aspirin but failed to overcome the goal of safer aspirin. As the method of prostaglandin inhibition through COX is a common mechanism to both the wanted and unwanted effects of aspirin and non-aspirin NSAIDs, the COX enzyme becomes a target for drug designers for the development of the “safe aspirin”. In the late 1990s, a new class of drug molecules collectively known as selective inhibitors of cyclooxygenase-2(Coxibs) was developed for the treatment of pain and inflammation. Coxibs developed were as efficacious as the common NSAIDs, but they are devoid of major side effect, the gastrointestinal bleeding. This review presents an overview on all the discovered COX-2 inhibitors, their physiological role, side effects and reasons of their withdrawal.
Export Options
About this article
Cite this article as:
Nandakishore Ravindran, Yalavarthi R. Prasanna, Kiran R. Yengala and Rajapranathi Malepati, Selective Cyclooxygenase Inhibitors: Current Status, Current Drug Discovery Technologies 2014; 11 (2) . https://dx.doi.org/10.2174/1570163811666140127123717
DOI https://dx.doi.org/10.2174/1570163811666140127123717 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Arterial Stiffness, Cognitive Dysfunction and Adherence to Antihypertensive Agents. Is there a Link to Hypertensive Patients?
Current Vascular Pharmacology Safety and Efficacy of Aliskiren in the Treatment of Hypertension and Associated Clinical Conditions
Current Drug Safety On Sports And Genes
Recent Patents on DNA & Gene Sequences Automated Office Blood Pressure-Eliminating White Coat Hypertension in Clinical Practice
Current Hypertension Reviews Meet Our Editorial Board Member
Current Signal Transduction Therapy Pigment Epithelium-Derived Factor (PEDF) Blocks Angiotensin IIInduced T Cell Proliferation by Suppressing Autocrine Production of Interleukin-2
Medicinal Chemistry Design, Synthesis and Molecular Docking Study of Some Substituted 4,5- dihydro-2H-indazole Derivatives as Potential Anti-inflammatory Agents
Medicinal Chemistry Ganoderma lucidum: A Potent Pharmacological Macrofungus
Current Pharmaceutical Biotechnology The Role of Coronary Physiology in Contemporary Percutaneous Coronary Interventions
Current Cardiology Reviews The Characteristics, Functions and Inhibitors of Three Aminopeptidases Belonging to the M1 Family
Current Protein & Peptide Science Pleiotropic Effects of Statins in Atherosclerotic Disease: Focus on the Antioxidant Activity of Atorvastatin
Current Topics in Medicinal Chemistry The Kidney and the Sympathetic System: A Short Review
Current Clinical Pharmacology Vasopressin Receptor Antagonists in Heart Failure
Recent Patents on Cardiovascular Drug Discovery Oxidative-Nitrosative Stress as a Contributing Factor to Cardiovascular Disease in Subjects with Diabetes
Current Vascular Pharmacology Coronary Artery Disease and Endothelial Dysfunction: Novel Diagnostic and Therapeutic Approaches
Current Medicinal Chemistry Do Folate, Vitamins B<sub>6</sub> and B<sub>12</sub> Play a Role in the Pathogenesis of Migraine? The Role of Pharmacoepigenomics
CNS & Neurological Disorders - Drug Targets 6-Chloro-7-methyl-3', 4'-dimethoxyflavone – a Potent Selective COX-2 Inhibitor
Medicinal Chemistry Stabilization of Neutral NH2-R-COOH Form of the Antihypertensive Peptides L-Valyl-L-Prolyl-L-Proline and L-Isoleucyl-L-Prolyl-L-Proline
Protein & Peptide Letters Renin--Angiotensin System Gene Polymorphism and Regression of Left Ventricular Hypertrophy in Hypertension
Current Pharmacogenomics Revised Roberts Cytoprotection and Adaptive Cytoprotection and Stable Gastric Pentadecapeptide BPC 157. Possible Significance and Implications for Novel Mediator
Current Pharmaceutical Design